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Background: Ga-[1,4,7,10-tetraazacyclododecane-N,N0,N00,N000-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE)
positron emission tomography (PET) is commonly used for the visualization of somatostatin receptor (SSTR)-positive
neuroendocrine tumors. SSTR is also known to be expressed on macrophages, which play a major role in
inflammatory processes in the walls of coronary arteries and large vessels. Therefore, imaging SSTR expression has
the potential to visualize vulnerable plaques. We assessed 68Ga-DOTATATE accumulation in large vessels in
comparison to 18F-2-fluorodeoxyglucose (FDG) uptake, calcified plaques (CPs), and cardiovascular risk factors.
Methods: Sixteen consecutive patients with neuroendocrine tumors or thyroid cancer underwent both
68Ga-DOTATATE and 18F-FDG PET/CT for staging or restaging purposes. Detailed clinical data, including common
cardiovascular risk factors, were recorded. For a separate assessment, they were divided into a high-risk and a
low-risk group. In each patient, we calculated the maximum target-to-background ratio (TBR) of eight arterial
segments. The correlation of the TBRmean of both tracers with risk factors including plaque burden was assessed.
Results: The mean TBR of 68Ga-DOTATATE in all large arteries correlated significantly with the presence of CPs
(r= 0.52; p< 0.05), hypertension (r= 0.60; p< 0.05), age (r= 0.56; p< 0.05), and uptake of 18F-FDG (r= 0.64; p< 0.01).
There was one significant correlation between 18F-FDG uptake and hypertension (0.58; p< 0.05). Out of the 37 sites
with the highest focal 68Ga-DOTATATE uptake, 16 (43.2%) also had focal 18F-FDG uptake. Of 39 sites with the
highest 18F-FDG uptake, only 11 (28.2%) had a colocalized 68Ga-DOTATATE accumulation.
Conclusions: In this series of cancer patients, we found a stronger association of increased 68Ga-DOTATATE uptake
with known risk factors of cardiovascular disease as compared to 18F-FDG, suggesting a potential role for plaque
imaging in large arteries. Strikingly, we found that focal uptake of 68Ga-DOTATATE and 18F-FDG does not colocalize
in a significant number of lesions.
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Cardiovascular disease (CVD) has become a global epi-
demic, being responsible for almost one third of all
recorded deaths in men and women worldwide [1,2].
Atherosclerosis is the leading cause of cardiovascular
disease morbidity, with the rupture of an atherosclerotic* Correspondence: Samnick_S@klinik.uni–wuerzburg.de
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in any medium, provided the original work is pplaque as the critical event resulting in either occlu-
sion of the vessel by a thrombus or thromboembolic
event [3].
Cardiovascular inflammatory processes with the accu-
mulation of activated macrophages on the vascular wall
play a crucial role in the initiation, progression,
destabilization, and eventually, rupture of vulnerable pla-
ques [4]. Therefore, inflammation constitutes an import-
ant target for imaging and treating atherosclerosis [5].
There are several invasive methods that can be used to
detect atherosclerotic plaques, such as intravascularen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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or angiography [8], which is still considered the gold
standard. However, due to their invasive nature, they are
not recommended for routine clinical application. Nu-
merous noninvasive imaging techniques have been ap-
plied to visualize vulnerable plaques, such as MRI and
high-frequency ultrasound [9,10]. Recently, other new
innovative sensitive imaging methods have been devel-
oped [11,12].
Due to its ability to process both structural and func-
tional information, positron emission tomography
(PET)/computed tomography (CT) holds great potential
in the evaluation of vulnerable plaques. As inflammation
detection has become the major concept in atheroscler-
osis PET/CT imaging, a more sensitive tracer is still to
be found. [1,4,7,10-tetraazacyclododecane-N,N0,N00,N000-
tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE)
labeled with a generator-derived positron-emitting iso-
tope Gallium-68 (68Ga) selectively binds to somatostatin
receptor 2 (SSTR-2). 68Ga-DOTATATE is routinely used
for the staging and restaging of neuroendocrine tumors.
Importantly, SSTR-2 was also found specifically
expressed and upregulated in human macrophages [13-
15], suggesting detection by 68Ga-DOTATATE PET im-
aging. Recently, 68Ga-DOTATATE as a more specific al-
ternative to the assessment of macrophages with PET/
CT has been published [16]. This tracer may potentially
be used as a tool to quantify the extent of atherosclerotic
inflammatory activities in big arteries.
Also, [18F]-2-fluorodeoxyglucose (FDG), as the most
commonly used radiotracer, has already been assessed
by several groups [17-19]. Results showed a good correl-
ation between carotid plaque 18F-FDG uptake in vivo
and macrophage staining from the corresponding histo-
logical sections [20,21]. Furthermore, there was a weak
but highly significant correlation between 18F-FDG up-
take and cardiovascular risk factors like hypertension,
smoking, hyperlipidemia, being overweight, type II dia-
betes, and a family history of coronary artery disease
(CAD) [22].
The purpose of this retrospective study was to exam-
ine the relationship of focal vascular 68Ga-DOTATATE
uptake to commonly known risk factors for cardiovascu-
lar disease and calcification. We also performed a correl-
ation to vascular 18F-FDG uptake, which has been
demonstrated to be a marker for atherosclerotic inflam-
mation in large arteries [23-26].
Methods
Patients
A total of 16 patients (12 males and 4 females, age
ranges from 48 to 77 years, mean age was 63.5 years)
were retrospectively reviewed by two experienced nu-
clear medicine physicians (MCK and CL). These patientshad undergone both 68Ga-DOTATATE PET/CT and 18F-
FDG PET/CT for staging or restaging within 6 weeks
(mean, 3.8 weeks; range, 0.14 to 5.9). None of these
patients received steroids or had a recent history of in-
flammation or vasculitis. The study protocol complied
with the Declaration of Helsinki; all patients gave their
informed consent for the studies.
Imaging procedures
All patients underwent 18F-FDG PET/CT and 68Ga-
DOTATATE PET/CT on a dedicated PET/CT scanner
(Siemens Biograph W mCT 64, Siemens, Knoxville, USA)
consisting of a LSO full-ring PET and a 64-slice spiral
CT. On the day of the 18F-FDG PET imaging, patients
fasted for at least 6 h to assure a serum glucose level
below 130 mg/dL. At the time point of intravenous in-
jection of 4.18 ± 0.88 MBq/kg bodyweight, patients
received 10 mg of furosemide i.v. After an uptake period
of 80 to 90 min, transmission data were acquired using a
low-dose CT (30 mAs, 120 kV, a 512 × 512 matrix, a 5-
mm slice thickness, an increment of 30 mm/s, a rotation
time of 0.5 s, and a pitch index of 0.8) extending from
the base of the skull, or the vertex, to the proximal
thighs. Consecutively, PET emission data were acquired
in three-dimensional mode with a 200 × 200 matrix with
2-min emission time per bed position. After decay and
scatter correction, PET data were reconstructed itera-
tively with attenuation correction using a dedicated soft-
ware (HD. PET, Siemens Esoft).
For the assessment of somatostatin receptor expres-
sion, a mean dose of 1.29 ± 0.43 MBq 68Ga-DOTATATE/
kg bodyweight was injected intravenously. After a period
of 40 to 60 min, CT and PET data acquisition was
started using the same parameters as mentioned above.
Image analysis
All PET/CT scans were reviewed for anatomic
localization and amount of focal tracer uptake. In each
patient, eight segments of large arteries were analyzed:
left carotid artery, right carotid artery, ascending thor-
acic aorta, aortic arch, descending thoracic aorta, ab-
dominal aorta, and left and right iliac arteries.
Arterial calcifications were also assessed; vascular
attenuation of >130 Hounsfield units was rated as calci-
fication [27,28]. The plaque burden was semiquantita-
tively determined by assessing the maximal dimensions
and composition of plaque using a scoring system from
0 to 4, as previously described by Rominger et al. [16]
(Table 1).
For PET data analysis, a region of interest (ROI)-based
approach was chosen. Maximal ‘standardized uptake
values’ (SUVmax) for both
18F-FDG and 68Ga-DOTATATE
uptake were calculated for all the segments mentioned
above [29]. Areas in proximity to tumor lesions or organs
Table 1 Calcified plaque scoring system
Score Calcified occupation of the vessel circumference (%)
0 0
1 <10
2 10 to 25
3 25 to 50
4 >50
The total calcified plaque burden for each of the eight arterial segments was
defined as the sum of the individual calcified plaque scores.
Table 2 Patient characteristics
Characteristics
Age (yrs) 63.5 ± 8.8
Gender (M, F) 4, 12
Hypercholesterolemia (%) 31.25
Hypertension (%) 56.25
Smoking (%) 25
Diabetes mellitus (%) 12.5
Family history of CAD (%) 25
History of CVD (%) 18.75
CPB 9.44 ± 8.07
CAD, coronary artery disease; CVD, cardiovascular disease; CPB, calcified
plaque burden; F, female; M, male.
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carefully avoided. At least three fixed-size ROIs were
placed to cover the lumen at each site, and the highest
value was extracted for the final calculation of target-to-
background ratios (TBRs). Background was defined as the
average blood-pool uptake as determined by the mean
SUV of six different ROIs (diameter of 1 cm) within the
lumen of the vena cava. The SUVmax was divided by the
mean blood-pool SUV in order to obtain the TBR [22].
We used the TBRs of all eight arterial segments for the
final analysis. To determine whether sites of increased
focal uptake of 18F-FDG and 68Ga-DOTATATE colocalize,
the sites with the highest uptake (within about 30% of the
highest uptake value) were assessed. Accordingly, arbitrary
cutoff TBR values of 3.5 for 68Ga-DOTATATE and 2.1 for
18F-FDG were chosen, resulting in 37 foci of increased
68Ga-DOTATATE uptake and 39 foci of increased FDG
uptake. Each of these foci was visually assessed for the
presence of concordantly increased focal uptake of the
other tracer and for the presence of calcifications in the
vessel wall.
We also assessed the differential vascular uptake of the
two tracers in a low-risk group for CAD, defined as sub-
jects with no more than one cardiovascular risk factor
(n= 8), and a high-risk group with at least two cardio-
vascular risk factors (n= 8). For ROI assignment,
visualization of PET/CT images, and automated coregis-
tration of the two PET/CT datasets, a dedicated software
(TrueD, Siemens Healthcare) was used.
Statistical methods
Statistical Package for Social Sciences (SPSS version
11.0; SPSS Inc. (IBM), Armonk, NY, US) was used for
statistical analyses. Continuous variables with a normal
distribution were recorded as mean ± standard devi-
ation. The site-specific blood-pool activities of the two
tracers were compared using ANOVA. Pearson correl-
ation coefficients were used for the assessment associ-
ation between the uptake of the two tracers and the
presented cardiovascular risk factors: plaque burden,
hypercholesterolemia, hypertension, smoking, diabetes,
family history, history of cardiovascular disease, body
mass index (BMI), age, and gender. Moreover, intraclass
correlation coefficients (ICCs) with 95% confidenceintervals were calculated to test interobserver and
intraobserver agreement for TBR. Two-way random ICC
values that are greater than 0.8 are accepted as a meas-
ure of excellent reproducibility [30].
Results
Patient population
Relevant baseline characteristics of the patients are
reported in Table 2. In brief, 8 out of 16 patients had a
history of neuroendocrine tumors, three suffered from
thyroid cancer, and the remaining five patients had dif-
ferent carcinomas. Systemic tumor therapy preceding
imaging for less than 12 weeks was administered in four
patients. Detailed information on tumor types and ther-
apies can be found in Table 3, and cardiovascular risk
factors can be found in Table S6 in Additional file 1.
PET/CT imaging
When assessing the PET/CT image data, we found colo-
calized uptake of both tracers (Figure 1) as well as foci
of increased uptake of only one of the tracers (Figures 2
and 3). On evaluation of the 37 sites with the highest
68Ga-DOTATATE TBR value, a colocalized focal in-
crease of 18F-FDG uptake was observed in 43.2% (16
sites, 10 sites with calcification, and 6 sites without calci-
fication), while 56.8% of the sites (21 sites, 6 sites with
calcification, and 15 sites without calcification) were
negative. Of 39 sites with the highest 18F-FDG uptake,
only 28.2% had an increased uptake of 68Ga-DOTATATE
(11 sites, 4 sites with calcification, and 7 sites without
calcification), while 71.8% of the sites (28 sites, 6 sites
with calcification, and 22 sites without calcification)
were recorded as negative (Figure 4). In total, 12 patients
were examined to have focal increased uptakes of
68Ga-DOTATATE, while 10 patients were found to
have 18F-FDG focal increased uptakes. As previously
recommended, we also used the mean TBR, which
was calculated as the mean value of TBRs from eight
arterial segments, for statistical analyses.
Table 3 Baseline characteristics of the study population
Patient
number
Cancer type Systemic tumor therapy within
the last 3 months
Number of selected
positive-uptake segments
TBRmean
FDG DOTATATE FDG DOTATATE
1 Renal cell cancer None 8 6 2.9 5.6
2 Follicular thyroid cancer TSH-suppressive therapy 7 2 2.6 3.3
3 Pheochromocytoma, metabolically active
(normetanephrines, dopamines)
None 3 4 2.1 3.9
4 Cancer of the gastric-esophageal junction Xeloda, single dose 2 days prior to FDG,
6 days prior to DOTATATE PET
0 0 1.5 1.8
5 NET (stomach) None 0 0 1.7 2.2
6 NET of unknown primary (liver metastases) None 6 3 2.2 3.4
7 Carcinoid (rectum) One cycle of Lu-177-DOTATATE 8 weeks
prior to FDG, 9 weeks to DOTATATE PET
0 1 1.7 2.9
8 NET of unknown primary (liver metastases) None 5 2 2.1 2.9
9 NET (pancreas) One cycle of cisplatin/etoposide 1 week
after FDG; 4 weeks prior to DOTATATE PET)
2 1 1.8 2.4
10 Carcinoid (lung), hormonally active None 1 2 1.7 2.6
11 NET of unknown primary (liver metastases) Sandostatin LAR, last injection 4 weeks
prior to DOTATATE PET, then stopped
0 0 1.5 2
12 NET (ileum) None 2 1 1.7 2.8
13 NSCLC None 1 8 1.8 5.7
14 Papillary and follicular thyroid cancer TSH-suppressive therapy 2 4 1.9 3.5
15 Follicular thyroid cancer TSH-suppressive therapy 2 3 1.9 3.1
16 Uterine cancer None 0 0 1.4 1.3
NET, neuroendocrine tumor; NSCLC, non-small cell lung cancer; TSH, thyroid-stimulating hormone.
Figure 1 Colocalized focal vascular uptake of 18F-FDG and 68Ga-DOTATATE. Transverse views of a 61-year-old male patient with
hypertension and a history of cardiovascular disease. Positive uptake is present on both 68Ga-DOTATATE (upper row) and 18F-FDG PET/CT (lower
row) at the same location in the abdominal aorta of this patient (red circle). Also, serious calcification was detected at the same position.
TBRDOTATATE was 6.18, while TRBFDG was 2.42.
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Figure 2 Focal vascular uptake of 68Ga-DOTATATE without corresponding focal 18F-FDG uptake. Transverse PET/CT images of a 73-year-
old male patient with hypertension, hypercholesterolemia, and smoking. Intense focal uptake of 68Ga-DOTATATE can be observed in the aortic
arch (upper row), whereas no focally increased 18F-FDG uptake was seen (lower row). TBRDOTATATE was 7.60, while TRBFDG was 1.74.
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Two risk-related groups were formed to assess the dif-
ferential vascular uptake of the two tracers. The summedFigure 3 Focal uptake of FDG but not DOTATATE in the vessel wall. T
hypertension, hypercholesterolemia, history of coronary disease and a fami
observed in the aortic arch (upper row), whereas no focally increased 68Ga
while TRBFDG was 2.50.calcification scores (CPsum) differed significantly between
the two groups (p < 0.05). The TBRmean, TBRabdominal,
TBRleft_iliac, and TBRright_iliac of
68Ga-DOTATATE wereransverse PET/CT images of a 77-year-old male patient. With
ly history of cardiovascular disease. Intense 18F-FDG uptake can be
-DOTATATE uptake can be seen (lower row). TBRDOTATATE was 1.64,
Figure 4 Colocalization of focal 68Ga-DOTATATE and 18F-FDG uptake. Comparison of 37 foci of increased 68Ga-DOTATATE uptake (left) and
39 foci of increased 18F-FDG uptake (right) with respect to colocalized focal uptake of the other radiotracer and calcification. Imaging findings
were characterized as concordant when there was agreement in positive detection with both tracers, and as discordant in cases of discrepancy
between the two tracers' uptake.
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two cardiovascular risk factors) as compared to the
low-risk group (one cardiovascular risk factor at the
most) (Figure 5). In contrast, for 18F-FDG, the
TBRmean and TBRabdominal only showed a tendency for
a higher uptake in the high-risk group; only the TBR
value in the left iliac artery was found to be significantly
higher (p < 0.05).
Correlation with risk factors
Table 4 shows the correlation of 18F-FDG and 68Ga-
DOTATATE TBRmean values with clinical baseline char-
acteristics. Hypertension significantly correlated with
18F-FDG (r = 0.58, p < 0.05) and also with 68Ga-
DOTATATE uptake (r= 0.60, p < 0.01). The 68Ga-
DOTATATE TBRmean also showed a significant correlation
with plaque burden (r = 0.52, p < 0.05), hypertension
(r= 0.60, p < 0.05), and age (r = 0.56, p < 0.05). In
addition, plaque burden was also significantly corre-
lated with smoking (r= 0.55, p < 0.05) and a history ofcardiovascular disease (r = 0.63, p < 0.01). There was a
significant correlation between the two tracers' uptake
(r= 0.64, p < 0.05).
Reproducibility
The intraclass correlation coefficient values with 95%
confidence were calculated for the maximum TBR and
CPB of all arteries and are shown in Table S3 in
Additional file 1. All ICCs were greater than 0.8.
Discussion
Our study was aimed at investigating the potential of
68Ga-DOTATATE PET/CT to detect macrophage dens-
ity at inflammatory lesions of large arteries. In
addition, we compared the tracer uptake with that of
18F-FDG regarding colocalization and intensity of the
uptake in correlation to commonly accepted risk fac-
tors for cardiovascular disease. To our knowledge, this
is the first investigation to compare 18F-FDG and
68Ga-DOTATATE in atherosclerosis imaging.
Figure 5 Comparison between high- and low-risk groups for cardiovascular disease. With regard to the 18F-FDG and 68Ga-DOTATATE
uptake of big arterial vessels and calcified plaques. One asterisk indicates that comparison is significant at the 0.05 level (two-tailed).
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to identify inflammatory processes, e.g., in large arteries
[17-22]. In general, it is taken up by cells in proportion
to their metabolic activity. Rudd et al. and Tawakol et al.
reported that carotid atherosclerotic plaques with high
18F-FDG uptake have a high macrophage density [20,21],
indicating that 18F-FDG might be a useful tool to detect
inflammatory plaques. 68Ga-DOTATATE has also been
demonstrated to detect activated macrophages [16] due
to a specific overexpression of the SSTR-2, the specific
molecular target of 68Ga-DOTATATE, on the cellTable 4 Correlation of 18F-FDG TBRmean and
68Ga-DOTATATE
characteristics
Pearson's correlation coefficients for the correlat
Mean
18F-FDG
Mean
68Ga-DOTATATE
PB Hyperchol H
Mean 18F-FDG 1 0.64a NS NS 0
Mean 68Ga-DOTATE 0.64a 1 0.52b NS 0
PB NS 0.52b 1 NS
aCorrelation is significant at the 0.01 level (two-tailed). bCorrelation is significant at
CVD, cardiovascular disease; DM, diabetes; HTN, hypertension; Hyperchol, hyperchosurface of activated macrophages. Although the potential
for macrophage detection has been demonstrated on
both 18F-FDG and 68Ga-DOTATATE, a concordant fo-
cally increased uptake was only found in the minority of
cases in this study (Figure 4).
When comparing patients with and without risk fac-
tors for cardiovascular disease, many sites of tracer up-
take could be detected both in high-risk and low-risk
patients with 18F-FDG. In most arterial segments (apart
from the ascending aorta), the maximum TBR values of
the high-risk group were higher than those of the low-TBRmean of eight arterial segments to the baseline
ion between risk factors and imaging results
TN Smoker DM Family history
of CVD
CVD Age Gender BMI
.58b NS NS NS NS NS NS NS
.60b NS NS NS NS 0.56b NS NS
NS 0.55b NS NS 0.63a NS NS NS
the 0.05 level (two-tailed). BMI, body mass index; CAD, coronary artery disease;
lesterolemia; NS, no significance; PB, plaque burden.
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tical significance except for the left iliac artery
(Figure 5).
There were few significant differences between the two
tracers in the low-risk group. In the high-risk group,
however, TBR for 68Ga-DOTATATE showed significantly
higher values than that for 18F-FDG.
Additionally, significant correlations between the mean
uptake of both tracers and the patients' score of risk fac-
tors were found. In the literature, several studies
reported significant correlations between focally
increased 18F-FDG uptake in the walls of large arteries
and the presence of cardiovascular risk factors, such as
hypercholesterolemia, hypertension, age, and diabetes
[24]. Other study groups found associations between the
plaque burden of the left anterior descending coronary
artery and cardiovascular risk factors [22,31]. In our
study, only a significant correlation between the mean
TBR in the abdominal aorta with hypertension was
found. The lack of further correlations might be due to
the small size of our sample. For 68Ga-DOTATATE,
tracer uptake correlated significantly with hypertension,
age, and the presence of calcifications.
18F-FDG uptake in inflammatory cells is influenced by
macrophage differentiation and cell activation [25] since
immune cell activation is associated with increased oxi-
dative metabolism and, consequently, increased use of
glucose [18]. In our investigation, we found many 18F-
FDG-positive sites both in the low- and high-risk
groups, whereas very few 68Ga-DOTATATE-positive foci
could be found in low-risk individuals. This raises doubt
whether all accumulations of 18F-FDG within the arter-
ies are due to macrophage-mediated inflammatory
activity.
In contrast to 18F-FDG, 68Ga-DOTATATE visualizes
the distribution of SSTR-2. As mentioned above, the
specific expression of SSTR-2 on the surface of macro-
phages, as well as the significant upregulation of this re-
ceptor upon stimulation (e.g. with lipopolysaccharide),
has been reported [14]. Furthermore, another research
group observed that the expression of SSTR-2 in human
coronary endothelial cells is decreased by treatment with
the inflammatory cytokine TNF-α, which is mainly pro-
duced and secreted by activated macrophages [26].
Therefore, in the pro-inflammatory setting, SSTR-2 ex-
pression is upregulated for macrophages, whereas on the
other hand, it is downregulated in endothelial cells. In
coronary heart disease, this idea could support the use
of 68Ga-DOTATATE for the detection of vulnerable
plaques.
SSTR-2 also plays another role in atherosclerotic pla-
ques. Adams et al. demonstrated the increased expres-
sion of SSTR-2 when human umbilical vein endothelial
cells are proliferating, thereby suggesting its active rolein angiogenesis, which has been described in the context
of unstable plaques [32]. Consequently, 68Ga-DOTA-
TATE PET could be used to visualize unstable plaques
in two different ways: detection of activated macro-
phages as well as angiogenesis within the atherosclerotic
lesion [33]. Our results indicate that 68Ga-DOTATATE
PET detects a higher number of increased focal uptakes
in patients with high cardiovascular risk; this may be
used as a complementary imaging modality in the detec-
tion of inflammatory plaque by identifying somatostatin
receptor-positive sites within the arteries.
In this study, risk factors for CAD correlated less
strongly with foci of increased 18F-FDG uptake as com-
pared to those of 68Ga-DOTATATE. This might be
interpreted as an indication that 68Ga-DOTATATE is
more specific for the inflamed plaque. However, due to
the small sample size of our investigation, it is difficult
to draw firm conclusions. For example, another reason
for the observed difference between the two tracers
could be tracer kinetics. DOTATATE binds to the SSTR-
2, and thus, the uptake is potentially limited by the num-
ber of saturated SSTR-2 receptors. This is not the case
with FDG, which is continuously metabolized by acti-
vated macrophages. Otherwise, FDG as the smaller mol-
ecule is potentially more vulnerable to unspecific uptake
mechanisms like increased vascular permeability due to
inflammation. So, in theory, FDG should be more sensi-
tive than DOTATATE but potentially less specific, which
could explain the better correlation with different risk
groups.
Another important limitation is the lack of histological
validation of 68Ga-DOTATATE uptake. Due to the retro-
spective design, a selection bias cannot be excluded.
Also, this study was performed in cancer patients; there-
fore, our findings may be not generalizable to studies in
vascular disease. Especially, we cannot exclude the influ-
ence of anticancer therapies or the hormone action of
neuroendocrine tumors (Table 3). So far, no influence of
TSH-suppressive therapy or peptide receptor radio-
nuclide therapy (PRRT) on atherosclerosis has been pub-
lished. In the only patient with PRRT, the interval to the
PET scans was at least 8 weeks, so we do not expect any
interference. Also, none of the two patients on chemo-
therapy was immunodeficient, according to their white
blood cell count. However, further prospective studies in
a higher number of non-oncological patients are
warranted.
Conclusions
In this pilot trial, we found a stronger association of
increased 68Ga-DOTATATE uptake with known risk fac-
tors of cardiovascular disease as compared to 18F-FDG
in a limited number of oncological patients, suggesting a
potential role of this tracer for plaque imaging in the
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the focal uptake of 68Ga-DOTATATE and 18F-FDG does
not colocalize in a significant percentage of lesions. This
warrants further investigation on the distribution of the
two tracers within atherosclerotic plaques.
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